Aging

Alzheimers

Cancer

Covid-19

Diabetes

Hypertension

Neurology

Peptides

Eric McDonald – Activate Telomerase to Stop Telomere Loss, Studies and Data

Peptide - December 2020

Peptide Relaunch - March 2021

Peptide Summit Relaunch - December 2021

<h6>Kent Holtorf, MD</h6>
Hello, this is Dr. Kent Holtorf with another episode of the Peptide Summit, it&#8217;s now 2.0. And today
we&#8217;ll be interviewing Eric McDonald of TA Sciences. We&#8217;re gonna talk about activation of telomerase to stop telomere loss. Thank you so much Eric for being on and telomeres are really in the, you know, really hot in terms of regenerative medicine, but you guys have been at this for quite a while and, in Norway everyone&#8217;s, you know, the cutting edge, but you were cutting edge cutting edge a long time ago. Give me, tell me a little history, how how&#8217;d you get into this?
&nbsp;
<h6>Eric Macdonald</h6>
How I got into it? I started the company seven years, you know, seven years ago. I started with them and the company itself was incorporated in 2002. It was founded by Knoll Patton. Who&#8217;s our founder and chairman, and he acquired the molecule from a biotech company in California called Geron and Geron is still in existence in this day, but they were looking to try to produce a molecule as a drug. So they were looking for it to be a pharmaceutical agent. And when they realized that the FDA was not, you know, ready for a anti-aging product they, they did maybe the stage left with this thing. They did a ton of studies in the nineties on this product and they knew they had something that was good. It&#8217;s just that, you know, it would never get approved at that time. And still here we are 2021 and the FDA is looking at, you know, aging products. So yeah,
&nbsp;

https://drsummits.s3.us-west-1.amazonaws.com/Peptide+Summit/Transcript/Eric-McDonald-Transcript-1.pdf

Eric McDonald completed his education at Michigan State University, earning a BS degree in Biology in the mid 80’s. After graduation, he started with Parke-Davis Pharmaceuticals. The blockbuster medications Eric launched included Lipitor (atorvastatin), Lopid (gemfibrozil), and Cognex (tacrine). He quickly rose from the ranks of field sales to leadership, culminating with a directorship position. During his fourteen year tenure, he held positions in Sales Management, Sales Training, and Marketing Operations.
Following Pfizer’s acquisition of Parke-Davis, Eric went in to hold Director of Sales positions of 5 years each at Doak Dermatologics and Taro Pharma.
In 2013, Eric decided to engage in regenerative medicine. He began with T.A. Sciences and hasn’t looked back. Eric assumed the Director of Sales position and quickly articulated the domestic operations US, cultivating key opinion leaders within the Telomere Biology field.

Eric McDonald

Kent Holtorf, MD is the medical director of the Holtorf Medical Group (www.HoltorfMed.com) and the founder and medical director of the non-profit National Academy of Hypothyroidism (NAH) (www.NAHypothyroidism.org), which is dedicated to the dissemination of new information to doctors and patients on the diagnosis and treatment of hypothyroidism. He is also the founder of Integrative Peptides (IntegrativePeptides.com), which is dedicated to the training of physicians regarding ground-breaking peptide therapies for their patients and bringing the highest quality peptides via supplement and unique delivery forms to doctors and patients, having the first and only BPC-157 in supplement version.

Eric McDonald – Activate Telomerase to Stop Telomere Loss, Studies and Data

Kent Holtorf, MD

Eric McDonald

Summary

Content Provided By

Kent Holtorf, MD

Guest Experts

Eric McDonald